Par Drugs & Chemicals Ltd Valuation Shifts Amid Market Rally

Valuation Metrics and Recent Changes

As of 1 September 2026, Par Drugs & Chemicals Ltd trades at ₹117.35, up from a previous close of ₹100.21. The stock’s 52-week range spans ₹78.05 to ₹122.43, indicating it is currently near its annual high. The company’s P/E ratio stands at 9.97, a figure that has contributed to the downgrade of its valuation grade from attractive to fair on 26 August 2026. This P/E is relatively modest, especially when contrasted with several peers in the Chemicals & Petrochemicals sector, many of whom exhibit significantly higher multiples.

For instance, J.G. Chemicals, a peer with a fair valuation grade, trades at a P/E of 33.01, while I G Petrochemicals and Titan Biotech are classified as very expensive with P/E ratios of 20.22 and 46.34 respectively. This disparity highlights Par Drugs & Chemicals’ comparatively conservative valuation, despite the recent reclassification.

Similarly, the company’s price-to-book value ratio is 1.29, which remains reasonable and suggests that the stock is not excessively priced relative to its net asset value. Other valuation multiples such as EV to EBIT (6.33), EV to EBITDA (5.14), and EV to sales (0.94) further reinforce the notion of fair valuation, especially when benchmarked against the sector’s more richly valued constituents.

Financial Performance and Quality Metrics

Par Drugs & Chemicals’ return on capital employed (ROCE) is a healthy 19.15%, while return on equity (ROE) stands at 12.94%. These figures indicate efficient utilisation of capital and reasonable profitability, supporting the company’s valuation despite the recent downgrade. The PEG ratio, which factors in earnings growth, is relatively elevated at 4.28, signalling that the stock’s price may be outpacing its earnings growth potential, a factor likely influencing the shift to a hold rating.

The company’s Mojo Score currently sits at 68.0, with a Mojo Grade of Hold, downgraded from Buy on 26 August 2026. This reflects a more cautious stance from analysts, balancing the company’s solid fundamentals against valuation concerns and market dynamics.

Comparative Valuation within the Sector

When analysing Par Drugs & Chemicals alongside its peer group, the company’s valuation appears conservative. Several competitors are trading at significantly higher multiples, reflecting either stronger growth prospects or market exuberance. For example, Oriental Aromatics is priced at a P/E of 295.42, categorised as expensive, while Keltech Energies trades at a P/E of 51.93, also very expensive. This contrast underscores the relative value proposition that Par Drugs & Chemicals offers, despite the recent shift to a fair valuation grade.

Other peers such as DCW and Platinum Industries also hold fair valuation grades but trade at higher P/E ratios of 18.88 and 25.37 respectively. This suggests that Par Drugs & Chemicals may still be undervalued relative to some of its sector counterparts, although the elevated PEG ratio tempers this view.

Stock Performance Relative to Market Benchmarks

Par Drugs & Chemicals has outperformed the Sensex over multiple time horizons in 2026. The stock delivered a 15.67% return over the past week and an 18.66% gain over the last month, while the Sensex declined by 0.57% and 1.24% respectively during the same periods. Year-to-date, the stock has appreciated by 15.89%, contrasting with a 7.84% decline in the Sensex. Even over the one-year horizon, the stock’s return of 18.86% surpasses the Sensex’s marginal fall of 1.42%.

However, longer-term performance reveals challenges, with a three-year return of -37.4% compared to the Sensex’s 25.07% gain. This divergence highlights the cyclical nature of the company’s business and the importance of valuation discipline when considering investment decisions.

Market Capitalisation and Micro-Cap Status

Par Drugs & Chemicals is classified as a micro-cap stock, which typically entails higher volatility and risk compared to larger companies. This status, combined with the recent valuation grade downgrade, suggests that investors should approach the stock with measured expectations, balancing the potential for price appreciation against inherent risks.

Investment Outlook and Conclusion

Par Drugs & Chemicals Ltd’s recent valuation shift from attractive to fair reflects a recalibration of market expectations amid strong price gains and a relatively high PEG ratio. While the company’s P/E and P/BV ratios remain modest compared to many peers, the elevated PEG ratio suggests that earnings growth may not fully justify the current price level. The downgrade to a Hold rating and a Mojo Grade of 68.0 further emphasise a more cautious stance.

Investors should weigh the company’s solid profitability metrics, including a ROCE of 19.15% and ROE of 12.94%, against the risks associated with its micro-cap status and recent valuation adjustments. The stock’s outperformance relative to the Sensex in the short term is encouraging, but longer-term underperformance signals the need for careful analysis before committing capital.

In summary, Par Drugs & Chemicals offers a fair valuation with reasonable price multiples and strong operational metrics, but the recent reclassification and high PEG ratio warrant a prudent approach. Investors seeking exposure to the Chemicals & Petrochemicals sector may consider this stock as part of a diversified portfolio, while also exploring alternative opportunities within the sector that may offer superior risk-adjusted returns.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today